104 results match your criteria: "and The George Washington University School of Medicine[Affiliation]"
Pediatr Crit Care Med
January 2025
Department of Pediatrics, Division of Critical Care Medicine, Children's National Hospital and The George Washington University School of Medicine and Health Sciences, Washington, DC.
Objectives: To examine the relationship between adequacy of caloric nutritional support during the first week after severe traumatic brain injury (TBI) and outcome.
Design: Single-center retrospective cohort, 2010-2022.
Setting: Tertiary care children's hospital with a level 1 trauma center.
Ann Intern Med
December 2024
The Edward P. Evans Precision Oncology Center of Excellence, Washington DC VA Medical Center, and The George Washington University School of Medicine, Washington, DC.
Pediatr Neurol
December 2024
Departments of Pediatrics and Population Health Sciences, Duke University School of Medicine, Durham, NC, USA, Duke-Margolis Center for Health Policy, Washington, District of Columbia. Electronic address:
Background: Parents of neonates with seizures report persistent symptoms of depression, anxiety, and posttraumatic stress. We aimed to characterize the parent experience of caring for children impacted by neonatal seizures, including longitudinal assessment across childhood.
Methods: This prospective, observational, multicenter study was conducted at Neonatal Seizure Registry (NSR) sites in partnership with the NSR Parent Advisory Panel.
MedEdPORTAL
September 2024
Professor, Department of Pediatrics, Larner College of Medicine at The University of Vermont.
Introduction: Research has shown the importance of diversity in improving patient care. Medical students from backgrounds underrepresented in medicine (UIM) face unique challenges, including minority tax, stereotype threat, and expectations to be the sole representative of their identity group. Mentors must be aware of these challenges and develop skills to address them.
View Article and Find Full Text PDFEClinicalMedicine
October 2024
Division of Cardiology, Department of Pediatrics, Oregon Health and Science University-Doernbecher Children's Hospital, Portland, OR, USA.
Pediatr Crit Care Med
October 2024
All authors: Department of Pediatrics, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington, DC.
Objectives: To examine career trajectory and academic profile of Pediatric Critical Care Medicine (PCCM) physicians, with special focus on gender differences.
Design: Observational cross-sectional study of PCCM fellowship graduates using publicly available data.
Setting: Publicly available databases including National Provider Identifier registry, American Board of Pediatrics, Doximity, official hospital websites, and Scopus.
JAMA Netw Open
June 2024
Department of Paediatrics, University of Melbourne, Parkville, Australia.
Importance: The use of evidence-based standardized outcome measures is increasingly recognized as key to guiding clinical decision-making in mental health. Implementation of these measures into clinical practice has been hampered by lack of clarity on what to measure and how to do this in a reliable and standardized way.
Objective: To develop a core set of outcome measures for specific neurodevelopmental disorders (NDDs), such as attention-deficit/hyperactivity disorder (ADHD), communication disorders, specific learning disorders, and motor disorders, that may be used across a range of geographic and cultural settings.
J Pediatr
September 2024
Novo Nordisk Inc, Plainsboro, NJ.
Objective: To assess cognitive, behavioral, and adaptive functions in children and young adults with hemophilia treated according to contemporary standards of care.
Study Design: Evolving Treatment of Hemophilia's Impact on Neurodevelopment, Intelligence, and Other Cognitive Functions (eTHINK) is a US-based, prospective, cross-sectional, observational study (September 2018 through October 2019). Males (aged 1-21 years) with hemophilia A or B of any severity, with or without inhibitors, were eligible.
AIDS Res Ther
May 2024
Centre of Excellence for Health, Immunity, and Infections, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Background: Human genetic contribution to HIV progression remains inadequately explained. The type 1 interferon (IFN) pathway is important for host control of HIV and variation in type 1 IFN genes may contribute to disease progression. This study assessed the impact of variations at the gene and pathway level of type 1 IFN on HIV-1 viral load (VL).
View Article and Find Full Text PDFRes Pract Thromb Haemost
February 2024
Cortica Healthcare and Children's Hospital Los Angeles, Westlake Village, California, USA.
Background: Nonacog beta pegol (N9-GP) is an extended half-life PEGylated factor (F)IX product with established efficacy and short-term safety in persons with hemophilia B (HB). Long-term safety has been evaluated for polyethylene glycol exposure but not N9-GP.
Objectives: To assess safety, neurodevelopmental, and efficacy outcomes of children with HB receiving N9-GP prophylaxis across 2 open-label, single-arm, phase 3 studies: paradigm5 (previously treated patients [PTPs]) and paradigm6 (previously untreated patients [PUPs]) in this interim analysis.
Cancer
July 2024
Division of Oncology and Department of Pediatrics, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
Background: On the fifth National Wilms Tumor Study, treatment for clear cell sarcoma of the kidney (CCSK) included combined vincristine, doxorubicin, cyclophosphamide, and etoposide (regimen I) plus radiation therapy (RT), yielding 5-year event-free survival (EFS) rates of 100%, 88%, 73%, and 29% for patients who had with stage I, II, III, and IV disease, respectively. In the Children's Oncology Group study AREN0321 of risk-adapted therapy, RT was omitted for stage I disease if lymph nodes were sampled, and carboplatin was added for stage IV disease (regimen UH-1). Patients who had stage II/III disease received regimen I with RT.
View Article and Find Full Text PDFLeukemia
April 2024
Department of Biostatistics, Colleges of Medicine, Public Health and Health Professions, University of Florida, Gainesville, FL, USA.
Clin Cancer Res
June 2024
Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration, Silver Spring, Maryland.
In October 2022, the FDA Oncology Center of Excellence hosted an educational symposium entitled, "Considering Functional Outcomes as Efficacy Endpoints in Pediatric Low-Grade Glioma (pLGG) Clinical Trials." The symposium brought together patient advocates, regulators from the FDA and the European Medicines Agency (EMA), and an international group of academic thought leaders in the field of pediatric neuro-oncology to discuss the potential role of functional outcomes, including visual acuity, motor function, and neurocognitive performance, as endpoints in clinical trials enrolling patients with pLGG. The panel discussed challenges and opportunities regarding the selection, implementation, and evaluation of clinical outcome assessments in these functional domains and outlined key considerations for their inclusion in future clinical trial design and role in new drug development.
View Article and Find Full Text PDFTransfusion
March 2024
Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.
Background: The Mirasol® Pathogen Reduction Technology System was developed to reduce transfusion-transmitted diseases in platelet (PLT) products.
Study Design And Methods: MiPLATE trial was a prospective, multicenter, controlled, randomized, non-inferiority (NI) study of the clinical effectiveness of conventional versus Mirasol-treated Apheresis PLTs in participants with hypoproliferative thrombocytopenia. The novel primary endpoint was days of ≥Grade 2 bleeding with an NI margin of 1.
Cancer
March 2024
Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts, USA.
Background: Patients with stage IV favorable histology Wilms tumor (FHWT) with extrapulmonary metastases (EPM) constitute a small subset of patients with FHWT. Because of their rarity and heterogeneity, optimal FHWT treatment is not well understood. Children's Oncology Group protocol AREN0533 assigned patients with FHWT and EPM to intensified chemotherapy, regimen M, after initial DD-4A chemotherapy.
View Article and Find Full Text PDFPediatr Crit Care Med
September 2023
Department of Pediatrics, Division of Critical Care Medicine, Children's National Hospital and The George Washington University School of Medicine and Health Sciences, Washington, DC.
Objectives: Test the hypothesis that within patient clinical instability measured by deterioration and improvement in mortality risk over 3-, 6-, 9-, and 12-hour time intervals is indicative of increasing severity of illness.
Design: Analysis of electronic health data from January 1, 2018, to February 29, 2020.
Setting: PICU and cardiac ICU at an academic children's hospital.
PLoS Comput Biol
January 2023
Center for Genomic Medicine, Rigshospitalet, Copenhagen, Denmark.
Background: Infection with human immunodeficiency virus type 1 (HIV) typically results from transmission of a small and genetically uniform viral population. Following transmission, the virus population becomes more diverse because of recombination and acquired mutations through genetic drift and selection. Viral intrahost genetic diversity remains a major obstacle to the cure of HIV; however, the association between intrahost diversity and disease progression markers has not been investigated in large and diverse cohorts for which the majority of the genome has been deep-sequenced.
View Article and Find Full Text PDFAcad Med
March 2023
N. Shah is associate professor, Hospital Medicine Division, Children's National Hospital and The George Washington University School of Medicine and Health Sciences, Washington, DC.
Problem: Incorporating patient and family voices in the development of entrustable professional activities (EPAs) is not standard practice. Care of children with medical complexity (CMC) is an area of pediatrics that relies on family partnership, and families of CMC are ideal partners in EPA development given their expertise in their child's care and experience interacting with the health care system. The authors describe their model for partnering with families to develop EPAs and reflect on the unique contributions of family leaders to the process.
View Article and Find Full Text PDFNeurology
October 2022
From the Departments of Neurology and Pediatrics (K.B.N.), University of California, San Francisco, Benioff Children's Hospital San Francisco; Department of Pediatrics (J. Palaganas), Weill Cornell Medicine, New York Presbyterian Hospital; Departments of Neurology and Pediatrics (N.S.A., C.A.P.), Children's Hospital of Philadelphia and the University of Pennsylvania; Neurology Division (M.L.H.), Department of Pediatrics, The Ohio State University College of Medicine, Nationwide Children's Hospital, Columbus; Section of Child Neurology (R.M.), Department of Pediatrics, Children's Hospital Colorado and the University of Colorado, Aurora; Division of Neurology (M.M.), Department of Pediatrics, The Hospital for Sick Children and University of Toronto, Ontario, Canada; Section of Child Neurology (J. Piantino), Department of Pediatrics, Oregon Health & Science University, Portland; and Center for Neuroscience (E.W.), Children's National Hospital and the George Washington University School of Medicine and Health Science, Washington, D.C.
Cancer Nurs
February 2023
Author Affiliations: School of Nursing, Fudan University (Dr Cheng), Shanghai, China; Departments of Population Health Sciences and Pediatrics, Duke Cancer Institute, Duke University School of Medicine (Dr Reeve and Ms Mann), Durham, North Carolina; School of Nursing, Clemson University (Dr Withycombe), South Carolina; Division of Oncology, Children's National Hospital (Dr Jacobs); and Department of Pediatrics, The George Washington University (Dr Jacobs), Washington, DC; Department of Pediatric Oncology and Center for Population Sciences, Dana-Farber Cancer Institute and Boston Children's Hospital (Dr Mack), Boston, Massachusetts; Division of Pediatric Palliative Care and Division of Pediatric Oncology, Children's Hospital and Medical Center (Dr Weaver), Omaha, Nebraska; Department of Nursing Science, Professional Practice and Quality, Children's National Hospital (Drs Waldron and Hinds); and Department of Pediatrics, The George Washington University (Drs Waldron and Hinds), Washington, DC; Department of Pediatrics, University of Pittsburgh School of Medicine (Dr Mauer); and Division of Palliative Medicine and Supportive Care, UPMC Children's Hospital of Pittsburgh (Dr Mauer), Pennsylvania; Division of Quality of Life and Palliative Care, St. Jude Children's Research Hospital (Dr Baker), Memphis, Tennessee; and Division of Biostatistics & Study Methodology, Children's National Hospital (Dr Wang); and The George Washington University School of Medicine and Health Sciences (Dr Wang), Washington, DC.
Background: Some children and adolescents receiving chemotherapy experience few symptom-related adverse events, whereas others experience multiple adverse events. If oncology nurses could identify patients likely to have pronounced chemotherapy-related adverse events, tailored supportive care could be matched to these patients' symptom burdens.
Objective: The aim of this study was to identify symptom profiles in children and adolescents before and after chemotherapy, and the sociodemographic and psychological factors associated with profile classification and change.
JAMA
July 2022
Critical Care Research Group, Wesley Medical Research, St Andrew's War Memorial Hospital, Brisbane, Queensland, Australia.
Importance: In children undergoing heart surgery, nitric oxide administered into the gas flow of the cardiopulmonary bypass oxygenator may reduce postoperative low cardiac output syndrome, leading to improved recovery and shorter duration of respiratory support. It remains uncertain whether nitric oxide administered into the cardiopulmonary bypass oxygenator improves ventilator-free days (days alive and free from mechanical ventilation).
Objective: To determine the effect of nitric oxide applied into the cardiopulmonary bypass oxygenator vs standard care on ventilator-free days in children undergoing surgery for congenital heart disease.
Pediatr Res
February 2023
Department of Pediatric Newborn Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Purpose: The utility of circulating tumor DNA (ctDNA) analyses has not been established in the risk stratification of Wilms tumor (WT). We evaluated the detection of ctDNA and selected risk markers in the serum and urine of patients with WT and compared findings with those of matched diagnostic tumor samples.
Patients And Methods: Fifty of 395 children with stage III or IV WT enrolled on Children's Oncology Group trial AREN0533 had banked pretreatment serum, urine, and tumor available.
J Clin Oncol
June 2022
Division of Oncology, Children's National Hospital and the George Washington University School of Medicine and Health Sciences, Washington, DC.
Journal Journal of Clinical Oncology.
View Article and Find Full Text PDFNeurohospitalist
April 2022
Department of Pediatrics, Section of Child Neurology, Oregon Health & Science University, Portland, OR, USA.